Guided Therapeutics Inc. (OTCMKTS:GTHP) Short Interest Update

Guided Therapeutics Inc. (OTCMKTS:GTHP) saw a large decline in short interest in June. As of June 30th, there was short interest totaling 19,653 shares, a decline of 39.5% from the June 15th total of 32,466 shares. Based on an average daily trading volume, of 17,349 shares, the short-interest ratio is currently 1.1 days. Currently, 0.1% of the shares of the stock are sold short.

Guided Therapeutics Price Performance

OTCMKTS GTHP remained flat at $0.28 during mid-day trading on Friday. The company had a trading volume of 573 shares, compared to its average volume of 9,210. Guided Therapeutics has a 1 year low of $0.12 and a 1 year high of $0.54. The stock’s fifty day moving average is $0.23 and its 200 day moving average is $0.29. The company has a market capitalization of $27.02 million, a PE ratio of -7.00 and a beta of 0.72.

Guided Therapeutics (OTCMKTS:GTHP) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.